Technology and Vision

GT Biologics is founded on the intellectual property generated by its founder Professor Denise Kelly an internationally renowned scientist with over twenty years experience in gut immunology and immune-related disorders. She has worked in both the commercial sector as a post doc with Nestle, Lausanne, Switzerland and in academia with the Rowett Institute of Nutrition & Health, where she heads the Gut Immunology Division and is responsible for the scientific output of approximately 16 scientists.

The company has been set-up to exploit the intellectual property based on an understanding of the anti-inflammatory activity of the harmless gut bacterium Bacteroides thetaiotaomicron. Early work has demonstrated that this species exerts a potent anti-inflammatory effect when administered to animals and that it may have beneficial effects in the treatment of inflammatory bowel diseases (IBD), particularly Crohn’s disease and ulcerative colitis. These diseases present as a spectrum of clinical phenotypes rather than two distinct diseases and affect some 1.8 million people in the seven major markets and are currently medically incurable.

We aim to develop products targeting inflammatory gut diseases of varying severity. We currently have a strong evidence-based portfolio demonstrating that our new probiotic bacteria and a therapeutic protein derived from B. thetaiotaomicron exerts fast acting anti-inflammatory activity in several models of gut inflammatory diseases. Our aim is to progress these lead products and to demonstrate their potential in maintaining long-term disease remission. Our new technology is compatible with the growing trend for targeted biologics as ‘breakthrough medicines’ for treating a wide range of inflammatory diseases, including human IBD.

Business Opportunities |

For information about business opportunities with GT-Biologics, please contact either Dr Howard Marriage or Professor Denise Kelly